A breakthrough in pancreatic cancer treatment is here: Fred and Pamela Buffett Cancer Center now offers daraxonrasib, an investigational pill targeting a gene mutation in 90% of cases. Early results show patients living 13 months—nearly double the 6.5-month average—with chemo. No more infusions, just a daily pill at home. Available via expanded access for those with no other options, it’s already drawing attention after Senator Ben Sasse shared his diagnosis. Side effects include a manageable facial rash. The drug’s potential extends to lung and colorectal cancers too. Enrollments open for stage four patients who’ve failed chemo—Nebraska Medicine is coordinating. This could be a game-changer in the fight against aggressive cancers.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
